Evidence map›Paper›PMID 22503978›Full record

ArticleBiochemical and biophysical research communications2012

Serendipitous discovery of a novel protein signaling mechanism in heart failure.

Andrea M Vitello, Yanmei Du, Peter M Buttrick, Lori A Walker

Abstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Andrea M VitelloUniversity of Colorado, Department of Medicine, Division of Cardiology, Aurora, CO 80045, USA.
Yanmei Du
Peter M Buttrick
Lori A Walker
University of Colorado Denver · US

Funding

Fibroblasts and Mononuclear Fibrogenic Cells Drive Right Ventricular Pulmonary ArR01HL114887 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI BULL, TODD M, BUTTRICK, PETER N. · 2012 to 2016
$3.4M
Myofilament Function in Human Heart FailureR01HL077195 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BUTTRICK, PETER N. · 2005 to 2008
$1.8M
Biochemical Markers of Progressive Heart DiseaseR21HL104352 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI BUTTRICK, PETER N., WALKER, LORI ANN · 2011 to 2012
$421k
NHLBI NIH HHS R01 HL077195NHLBI NIH HHS R01 HL114887NHLBI NIH HHS R21 HL104352
6 · The paper itself

Abstract

A number of protein signaling mechanisms are known to be involved in the progression of heart failure, yet the mechanism(s) by which the heart fails remains poorly understood. Therefore, we undertook a global approach to this question and used an antibody microarray to identify proteins differentially expressed in dysfunctional right ventricles in a bovine model of heart failure and the results were validated using cardiac tissue from both bovine and human heart failure. We found that protein disulfide isomerase 3, PDIA3, a protein that resides in the lumen of the endoplasmic reticulum, is significantly upregulated in both animal and human models of right and left heart failure. Altered expression of this protein has not previously been described in models of heart failure. In our initial microarray analysis, we found that CSK (c-Src kinase) was among the proteins upregulated in failing bovine ventricle. To further elucidate the role of CSK in heart failure, we studied the expression of its downstream target, Src, and found that Src expression and phosphorylation were markedly upregulated in failing ventricles. However, we also noted a smaller immunologically reactive protein that was only seen in experimental animals. In order to positively identify the smaller, Src-reactive protein, we used 2-dimensional gel electrophoresis and mass spectrophotometry. Surprisingly, we identified this protein as PDIA3, a protein that did not belong to the Src family of proteins. Upon sequence examination we found that PDIA3 contains a short C-terminal sequence with strong homology to Src and that it was this short sequence to which the antibody was generated. PDIA3 participates in MHC class I presentation and is implicated in the progression of valvular dysfunction in rheumatic heart disease, as well as calcium modulation in the sarcoplasmic reticulum. The molecule resides in the lumen of the endoplasmic reticulum and participates in disulfide bond formation during protein folding by interacting with calnexin and calreticulin. This interaction may indirectly effect SERCA (sarco/endoplasmic reticulum Ca(2+)-transport ATPase) activity and by extension contribute to the calcium dysregulation that characterizes progressive heart failure. Further studies are needed to elucidate the role that PDIA3 may play in the progression of heart failure.

Indexed as

Amino Acid SequenceAnimalsAntibodies, MonoclonalAntigen PresentationCattleCells, CulturedDisease Models, AnimalEndoplasmic ReticulumHeart FailureHeart VentriclesHistocompatibility Antigens Class IHumansImmunodominant EpitopesMolecular Sequence DataProtein Array AnalysisProtein Disulfide-IsomerasesAntibodies, MonoclonalHistocompatibility Antigens Class IImmunodominant EpitopesPDIA3 protein, humanProtein Disulfide-IsomerasesSarcoplasmic Reticulum Calcium-Transporting ATPasessrc-Family Kinases

Identifiers

PMID22503978
PMCPMC3351564
OpenAlexW1993411128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.